Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypoxia-induced factor 1 | 0.0661 | 0.8475 | 0.8016 |
Loa Loa (eye worm) | hypothetical protein | 0.0717 | 1 | 1 |
Schistosoma mansoni | jun-related protein | 0.0365 | 0.0338 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0365 | 0.0338 | 0.5 |
Onchocerca volvulus | 0.0353 | 0 | 0.5 | |
Echinococcus multilocularis | jun protein | 0.0449 | 0.265 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription factor | 0.0449 | 0.265 | 0.5 |
Brugia malayi | bZIP transcription factor family protein | 0.0449 | 0.265 | 0.265 |
Brugia malayi | hypoxia-induced factor 1 | 0.0661 | 0.8475 | 0.8475 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription factor | 0.0449 | 0.265 | 0.5 |
Echinococcus granulosus | jun protein | 0.0449 | 0.265 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | > 33 uM | Inhibitory activity against cPLA2 (cytosolic Phospholipase A2) by measuring the calcium ionophore A-23,187-induced arachidonic acid release from bovine platelets | ChEMBL. | 9276015 |
IC50 (functional) | > 33 uM | Inhibitory activity against cPLA2 (cytosolic Phospholipase A2) by measuring the calcium ionophore A-23,187-induced arachidonic acid release from bovine platelets | ChEMBL. | 9276015 |
Inhibition (functional) | > 28 % | Inhibitory activity against cPLA2 (cytosolic Phospholipase A2) by measuring the calcium ionophore A-23,187-induced arachidonic acid release from bovine platelets at a compound conc of 33 uM | ChEMBL. | 9276015 |
Inhibition (functional) | > 28 % | Inhibitory activity against cPLA2 (cytosolic Phospholipase A2) by measuring the calcium ionophore A-23,187-induced arachidonic acid release from bovine platelets at a compound conc of 33 uM | ChEMBL. | 9276015 |
Lysis (functional) | = 0 % | The cell lytic potency at a compound concentration of 33 uM in bovine platelets was determined | ChEMBL. | 9276015 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.